Dedicator of cytokinesis 2 silencing therapy inhibits neointima formation and improves blood flow in rat vein grafts

Cao, Bojun; Wang, Xiaowen; Zhu, Lei; Zou, Rongjiang; Lu, Zhi-Qian

doi:10.1016/j.yjmcc.2019.01.030

Cited by 7 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, DOCK2 knockout was shown to increase VSMC marker protein expression, supporting an argument for the requirement of low level DOCK2 expression in VSMCs to maintain contractile protein homeostasis [74]. A further study has implicated a role for DOCK2 in neointima formation, which is the generation of scar tissue in the blood vessel lumen after vein graft [75]. This was identified when unusually high levels of DOCK2 expression were detected in vein grafts of male Sprague-Dawley rats that underwent jugular vein-carotid artery bypass grafting [75].…”

Section: Dock2mentioning

confidence: 89%

“…A further study has implicated a role for DOCK2 in neointima formation, which is the generation of scar tissue in the blood vessel lumen after vein graft [75]. This was identified when unusually high levels of DOCK2 expression were detected in vein grafts of male Sprague-Dawley rats that underwent jugular vein-carotid artery bypass grafting [75]. Adding to existing knowledge of the role of DOCK2 in VSMC differentiation, DOCK2 knockdown was noted to inhibit rat VSMC migration and proliferation, whereas over-expression significantly increased these processes [75].…”

Section: Dock2mentioning

confidence: 99%

“…This was identified when unusually high levels of DOCK2 expression were detected in vein grafts of male Sprague-Dawley rats that underwent jugular vein-carotid artery bypass grafting [75]. Adding to existing knowledge of the role of DOCK2 in VSMC differentiation, DOCK2 knockdown was noted to inhibit rat VSMC migration and proliferation, whereas over-expression significantly increased these processes [75]. As VSMC migration and proliferation are key processes in angiogenesis, these findings point towards a role for DOCK2 in the maintenance of healthy mammalian blood vessels.…”

Section: Dock2mentioning

confidence: 99%

“…As VSMC migration and proliferation are key processes in angiogenesis, these findings point towards a role for DOCK2 in the maintenance of healthy mammalian blood vessels. To further validate the involvement of DOCK2 in vessel maintenance, the knockdown of endogenous DOCK2 in grafted veins was shown to reduce neointimal formation and lead to improved hemodynamics in vein grafts [75]. Despite this clear association with vessel maintenance, DOCK2 has not yet been implicated in human vascular disease, but has been reported to cause an inherited immunodeficiency disorder [76].…”

Section: Dock2mentioning

confidence: 99%

See 3 more Smart Citations

The DOCK protein family in vascular development and disease

Benson

Southgate

2021

Angiogenesis

View full text Add to dashboard Cite

The vascular network is established and maintained through the processes of vasculogenesis and angiogenesis, which are tightly regulated during embryonic and postnatal life. The formation of a functional vasculature requires critical cellular mechanisms, such as cell migration, proliferation and adhesion, which are dependent on the activity of small Rho GTPases, controlled in part by the dedicator of cytokinesis (DOCK) protein family. Whilst the majority of DOCK proteins are associated with neuronal development, a growing body of evidence has indicated that members of the DOCK family may have key functions in the control of vasculogenic and angiogenic processes. This is supported by the involvement of several angiogenic signalling pathways, including chemokine receptor type 4 (CXCR4), vascular endothelial growth factor (VEGF) and phosphatidylinositol 3-kinase (PI3K), in the regulation of specific DOCK proteins. This review summarises recent progress in understanding the respective roles of DOCK family proteins during vascular development. We focus on existing in vivo and in vitro models and known human disease phenotypes and highlight potential mechanisms of DOCK protein dysfunction in the pathogenesis of vascular disease.

show abstract

Section: Dock2mentioning

confidence: 89%

Section: Dock2mentioning

confidence: 99%

Section: Dock2mentioning

confidence: 99%

Section: Dock2mentioning

confidence: 99%

See 2 more Smart Citations

The DOCK protein family in vascular development and disease

Benson

Southgate

2021

Angiogenesis

View full text Add to dashboard Cite

show abstract

“…It can inhibit the protein in the small intestine to transport cholesterol, thereby inhibiting the function of intestinal absorption of cholesterol, regulating plasma free cholesterol level, and reducing cholesterol storage level in the liver. This product can be used in combination with atorvastatin calcium to reduce LDL-C level [11] . While controlling a high-fat diet, it can be used independently to regulate blood lipids or in combination with HMG-CoA reductase inhibitors (statins) to treat hypercholesterolemia caused by various factors, which can significantly reduce plasma LDL-C, TC and Apolipoprotein B (ApoB) levels.…”

Section: Clinical Datamentioning

confidence: 99%

Clinical Efficacy of Atorvastatin Combined with Ezetimibe in Preventing Restenosis after Coronary Artery Bypass Grafting

Wei¹,

Wang²,

Wang³

et al. 2022

IJPS

View full text Add to dashboard Cite

Wei et al.: Efficacy of Atorvastatin Combined with Ezetimibe in Preventing RestenosisTo investigate the clinical efficacy of atorvastatin combined with ezetimibe in preventing restenosis after coronary artery bypass grafting. Total 100 patients in Tangshan Workers' Hospital were randomly divided into observation group and control group. The control group received 100 mg aspirin, 75 mg clopidogrel and atorvastatin 20 mg once a day. The observation group was given 10 mg ezetimibe once a day in addition to the above drugs. The venous diameter, blood lipid level changes, inflammatory response, quality of life, adverse reactions and treatment effects were assessed. After treatment for 6 mo, hypersensitive C-reactive protein and interleukin-6 levels were lower in observation group than control group. Total cholesterol, triglyceride and low-density lipoprotein cholesterol levels were lower and high-density lipoprotein cholesterol level was higher in observation group than control group. The observation group exhibited higher rates of vein garft stenosis improvement, lower rates of disease progression, lower incidence of major adverse cardiovascular events and higher 36-Item Short-Form Health survey scores than control group. The efficacy of ezetimibe combined with atorvastatin in treating restenosis after coronary artery bypass grafting is good, which also controls blood lipids with low incidence of adverse reactions.

show abstract